Comparative Pharmacology
Head-to-head clinical analysis: FOLEX PFS versus JYLAMVO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FOLEX PFS versus JYLAMVO.
FOLEX PFS vs JYLAMVO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Methotrexate is a folate analog that inhibits dihydrofolate reductase (DHFR), blocking the synthesis of tetrahydrofolate and thereby interfering with DNA synthesis, repair, and cellular replication. It also exhibits immunosuppressive and anti-inflammatory effects through inhibition of purine and pyrimidine synthesis and reduction of cytokine production.
JYLAMVO (methotrexate) is a folate analog that inhibits dihydrofolate reductase (DHFR), thereby disrupting DNA synthesis and repair. It also inhibits purine and thymidylate synthesis, leading to immunosuppressive and antineoplastic effects.
Methotrexate 30-40 mg/m2 IV once weekly or 7.5-15 mg PO once weekly as single dose or divided into 3 doses over 24 hours.
Oral: 30 mg twice daily for adults with relapsed or refractory acute myeloid leukemia (AML) as a monotherapy.
None Documented
None Documented
Terminal elimination half-life: 6-12 hours in patients with normal renal function. With impaired renal function, half-life is prolonged (up to 24-48 hours). Low-dose methotrexate (e.g., for rheumatoid arthritis) has half-life 3-10 hours. High-dose methotrexate has a triphasic elimination: alpha phase (0.75 hours), beta phase (3.5 hours), and terminal gamma phase (10-20 hours).
Terminal elimination half-life is 12-16 hours in adults with normal renal function; prolonged to 24-48 hours in severe renal impairment (CrCl <30 mL/min).
Primarily renal excretion as unchanged drug; approximately 80-90% excreted unchanged in urine within 24 hours. Biliary/fecal excretion is minimal (<10%).
Primarily renal elimination as unchanged drug (approximately 70-80%) with minor biliary/fecal excretion (20-30%).
Category C
Category C
Antineoplastic Agent
Antineoplastic Agent